Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 3/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864226 | 0.85 | LTA4H (0.47) | PSMB1PSMB5HRH3KCNH2ALDH1A1 | |
| SCHEMBL5863370 | 0.81 | LTA4H (0.61) | PSMB1PSMB5HRH3KCNH2LTA4H | |
| SCHEMBL5864259 | 0.78 | MCHR1 (0.55) | PSMB1PSMB5HRH3ALDH1A1MEN1 | |
| SCHEMBL5863673 | 0.75 | LTA4H (0.59) | HRH3KCNH2ALDH1A1LTA4HKDM4E | |
| SCHEMBL5863794 | 0.75 | LTA4H (0.46) | PSMB1PSMB5HRH3KCNH2LTA4H | |
| SCHEMBL5864125 | 0.75 | HRH3 (0.47) | PSMB1PSMB5HRH3KCNH2LTA4H | |
| SCHEMBL5863302 | 0.74 | LTA4H (0.47) | HRH3KCNH2ALDH1A1LTA4HKDM4E | |
| SCHEMBL5863641 | 0.74 | LTA4H (0.54) | HRH3KCNH2MEN1KMT2ALTA4H | |
| SCHEMBL5863668 | 0.73 | KDR (0.60) | HRH3MEN1KMT2ALTA4H | |
| SCHEMBL5863728 | 0.73 | LTA4H (0.51) | PSMB1PSMB5HRH3KCNH2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | PSMB1 2557/4885PSMB5 1457/4885HRH3 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.